Adamas Pharmaceuticals

Forest Labs, Adamas to develop fixed dose combo of Namenda XR and Donepezil for Alzheimer’s

Wednesday, November 14, 2012

Forest Laboratories, an international pharmaceutical company, and Adamas Pharmaceuticals, an Emeryville, Calif.-based therapeutics company focused on CNS disorders, have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer’s type in the U.S.

[Read More]